Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Generalized Additive Models: An Introduction with R

Wood, S. N. (2017) · doi:10.1201/9781315370279 · Cited by 13,852 · see citing works

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · see citing works

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897 · see citing works

Sensitivity analysis in observational research: Introducing the E-value

VanderWeele, T. J., & Ding, P. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2607 · Cited by 6,350 · see citing works

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983 · see citing works

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616 · see citing works

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742 · see citing works

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · see citing works

Cell entry mechanisms of SARS-CoV-2

Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A., & Li, F. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003138117 · Cited by 3,142 · see citing works

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109 · see citing works

Correlates of protection induced by vaccination

Plotkin, S. A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00131-10 · Cited by 1,745 · see citing works

A Case-Cohort Design for Epidemiologic Cohort Studies and Disease Prevention Trials

Prentice, R. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.1 · Cited by 1,444 · see citing works

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Bergwerk, M., Gonen, T., Lustig, Y., Amit, S., Lipsitch, M., Cohen, C., Mandelboim, M., Levin, E. G., Rubin, C., Indenbaum, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2109072 · Cited by 1,345 · see citing works

Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment

Wouters, O. J., Shadlen, K. C., Salcher‐Konrad, M., Pollard, A. J., Larson, H. J., Teerawattananon, Y., & Jit, M. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00306-8 · Cited by 1,291 · see citing works

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Feng, S., Phillips, D. J., White, T., Sayal, H., Aley, P. K., Bibi, S., Dold, C., Fuskova, M., Gilbert, S. C., Hirsch, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01540-1 · Cited by 1,163 · see citing works

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Feng, S., Phillips, D. J., White, T., Sayal, H., Aley, P. K., Bibi, S., Dold, C., Fuskova, M., Gilbert, S. C., Hirsch, I., et al. (2021) · doi:10.1101/2021.06.21.21258528 · Cited by 1,163 · see citing works

Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques

McMahan, K., Yu, J., Mercado, N. B., Loos, C., Tostanoski, L. H., Chandrashekar, A., Liu, J., Peter, L., Atyeo, C., Zhu, A., et al. (2021) · Nature · doi:10.1038/s41586-020-03041-6 · Cited by 1,068 · see citing works

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Yu, J., Tostanoski, L. H., Peter, L., Mercado, N. B., McMahan, K., Mahrokhian, S. H., Nkolola, J. P., Liu, J., Li, Z., Chandrashekar, A., et al. (2020) · Science · doi:10.1126/science.abc6284 · Cited by 997 · see citing works

Evidence for antibody as a protective correlate for COVID-19 vaccines

Earle, K. A., Ambrosino, D. M., Fiore-Gartland, A., Goldblatt, D., Gilbert, P. B., Siber, G. R., Dull, P., & Plotkin, S. A. (2021) · doi:10.1101/2021.03.17.20200246 · Cited by 870 · see citing works

Evidence for antibody as a protective correlate for COVID-19 vaccines

Earle, K. A., Ambrosino, D. M., Fiore-Gartland, A., Goldblatt, D., Gilbert, P. B., Siber, G. R., Dull, P., & Plotkin, S. A. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.05.063 · Cited by 870 · see citing works

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021

Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7013e3 · Cited by 707 · see citing works

New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications

Abdool Karim, S. S., & de Oliveira, T. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2100362 · Cited by 699 · see citing works

Complex Surveys: A Guide to Analysis Using R

Lumley, T. (2010) · doi:10.1002/9780470580066 · Cited by 647 · see citing works

Sensitivity Analysis Without Assumptions

Ding, P., & VanderWeele, T. J. (2016) · Epidemiology · doi:10.1097/ede.0000000000000457 · Cited by 576 · see citing works

Biomarkers and surrogate endpoints in clinical trials

Fleming, T. R., & Powers, J. H. (2012) · Statistics in Medicine · doi:10.1002/sim.5403 · Cited by 546 · see citing works

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

Poland, G., Ovsyannikova, I., & Kennedy, R. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32137-1 · Cited by 540 · see citing works

Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate

Addetia, A., Crawford, K. H. D., Dingens, A., Zhu, H., Roychoudhury, P., Huang, M.-L., Jerome, K. R., Bloom, J. D., & Greninger, A. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02107-20 · Cited by 525 · see citing works

SARS-CoV-2 Vaccines

Creech, C. B., Walker, S. C., & Samuels, R. J. (2021) · JAMA · doi:10.1001/jama.2021.3199 · Cited by 420 · see citing works

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

Shen, X., Tang, H., McDanal, C., Wagh, K., Fischer, W., Theiler, J., Yoon, H., Li, D., Haynes, B. F., Sanders, K. O., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.002 · Cited by 378 · see citing works

Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies

Siber, G. R., Chang, I., Baker, S. A., Fernsten, P. D., O’Brien, K. L., Santosham, M., Klugman, K. P., Madhi, S. A., Paradiso, P. R., & Kohberger, R. C. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.119 · Cited by 365 · see citing works

WHO International Standard for anti-SARS-CoV-2 immunoglobulin

Kristiansen, P. A., Page, M., Bernasconi, V., Mattiuzzo, G., Dull, P. M., Makar, K. W., Plotkin, S. A., & Knežević, I. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00527-4 · Cited by 356 · see citing works

Nomenclature for Immune Correlates of Protection After Vaccination

Plotkin, S. A., & Gilbert, P. B. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis238 · Cited by 348 · see citing works

Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

Corbett, K. S., Nason, M. C., Flach, B., Gagne, M., O’Connell, S., Johnston, T. S., Shah, S. N., Edara, V. V., Floyd, K., Lai, L., et al. (2021) · Science · doi:10.1126/science.abj0299 · Cited by 286 · see citing works

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial

Cohen, M. S., Nirula, A., Mulligan, M. J., Novak, R. M., Marovich, M., Yen, C., Stemer, A., Mayer, S. M., Wohl, D., Brengle, B., et al. (2021) · JAMA · doi:10.1001/jama.2021.8828 · Cited by 193 · see citing works

Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk

Neidich, S. D., Fong, Y., Li, S. S., Geraghty, D. E., Williamson, B. D., Young, W. C., Goodman, D. D., Seaton, K. E., Shen, X., Sawant, S. S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126391 · Cited by 119 · see citing works

Increasing Black, Indigenous and People of Color participation in clinical trials through community engagement and recruitment goal establishment

Andrasik, M. P., Broder, G. B., Wallace, S. E., Chaturvedi, R., Michael, N. L., Bock, S., Beyrer, C., Oseso, L. N., Aina, J., Lucas, J. P., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0258858 · Cited by 104 · see citing works

A General Framework for Inference on Algorithm-Agnostic Variable Importance

Williamson, B. D., Gilbert, P. B., Simon, N., & Carone, M. (2021) · Journal of the American Statistical Association · doi:10.1080/01621459.2021.2003200 · Cited by 90 · see citing works

Influenza Hemagglutination-inhibition Antibody Titer as a Mediator of Vaccine-induced Protection for Influenza B

Cowling, B. J., Lim, W. W., Perera, R. A. P. M., Fang, V. J., Leung, G. M., Peiris, M. J. S., & Tchetgen, E. J. T. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy759 · Cited by 74 · see citing works

Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques

He, X., Chandrashekar, A., Zahn, R., Wegmann, F., Yu, J., Mercado, N. B., McMahan, K., Martinot, A. J., Piedra-Mora, C., Beecy, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.05.040 · Cited by 65 · see citing works

Statistical Inference for Data Adaptive Target Parameters

Hubbard, A., Kherad-Pajouh, S., & van der Laan, M. J. (2016) · The International Journal of Biostatistics · doi:10.1515/ijb-2015-0013 · Cited by 63 · see citing works

Correlates of Protection

Plotkin, S. A., & Gilbert, P. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00003-1 · Cited by 43 · see citing works

Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features

Magaret, C. A., Benkeser, D. C., Williamson, B. D., Borate, B. R., Carpp, L. N., Georgiev, I. S., Setliff, I., Dingens, A. S., Simon, N., Carone, M., et al. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006952 · Cited by 39 · see citing works

A government-led effort to identify correlates of protection for COVID-19 vaccines

Koup, R. A., Donis, R. O., Gilbert, P. B., Li, A. W., Shah, N. A., & Houchens, C. R. (2021) · Nature Medicine · doi:10.1038/s41591-021-01484-6 · Cited by 31 · see citing works

Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial

Cromer, D., Reynaldi, A., Steain, M., Triccas, J. A., Davenport, M. P., & Khoury, D. S. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac075 · Cited by 23 · see citing works

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial

Sabo, J., McCulloh, R. J., Lorenzo, M. M. G., Clement, M. E., Ramírez, J. A., Lipson, B., Klekotka, P., Adams, A. C., Farrior, J., Naarden, J. S. V., et al. (2021) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/cew2-rc27 · Cited by 14 · see citing works

Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC) trial

(2021) · doi:10.1101/2021.06.29.21259504 · Cited by 12 · see citing works

Effectiveness of the mRNA BNT162b2 vaccine six months after vaccination: findings from a large Israeli HMOPreprint

Kertes, J., Gez, S. B., Saciuk, Y., Supino‐Rosin, L., Shamir-Stein, N., Mizrahi-Reuveni, M., & Zohar, A. E. (2021) · medRxiv · doi:10.1101/2021.09.01.21262957 · Cited by 7 · see citing works

Assessment of Immune Correlates of Protection via Controlled Vaccine Efficacy and Controlled RiskPreprint

Gilbert, P. B., Fong, Y., & Carone, M. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2107.05734 · Cited by 1 · see citing works

Efficient nonparametric estimation of the covariate-adjusted threshold-response function, a support-restricted stochastic interventionPreprint

van der Laan, L. W. P., Zhang, W., & Gilbert, P. B. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2107.11459

Detecting and describing heterogeneity in meta-analysis

Hardy, R. J., & Thompson, S. G. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980430)17:8

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Feng, S., Phillips, D. J., White, T., Sayal, H., Aley, P. K., Bibi, S., Dold, C., Fuskova, M., Gilbert, S. C., Hirsch, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01540-1 · Cited by 1,163 · see citing works

The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic

Hoffmann, M., Krüger, N., Schulz, S., Cossmann, A., Rocha, C., Kempf, A., Nehlmeier, I., Graichen, L., Moldenhauer, A.-S., Winkler, M. S., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.032 · Cited by 889 · see citing works

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

Goel, R. R., Painter, M. M., Apostolidis, S. A., Mathew, D., Meng, W., Rosenfeld, A. M., Lundgreen, K. A., Reynaldi, A., Khoury, D. S., Pattekar, A., et al. (2021) · Science · doi:10.1126/science.abm0829 · Cited by 873 · see citing works

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway

Willett, B. J., Grove, J., MacLean, O. A., Wilkie, C., De Lorenzo, G., Furnon, W., Cantoni, D., Scott, S., Logan, N., Ashraf, S., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01143-7 · Cited by 785 · see citing works

Homologous and Heterologous Covid-19 Booster Vaccinations

Atmar, R. L., Lyke, K. E., Deming, M. E., Jackson, L. A., Branche, A. R., Sahly, H. M. E., Rostad, C. A., Martin, J. M., Johnston, C., Rupp, R. E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116414 · Cited by 629 · see citing works

A Bivalent Omicron-Containing Booster Vaccine against Covid-19

Chalkias, S., Harper, C., Vrbicky, K., Walsh, S. R., Essink, B., Brosz, A., McGhee, N., Tomassini, J. E., Chen, X., Chang, Y., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208343 · Cited by 627 · see citing works

Humoral and cellular immune memory to four COVID-19 vaccines

Zhang, Z., Mateus, J., Coelho, C. H., Dan, J. M., Moderbacher, C. R., Gálvez, R. I., Côrtes, F. H., Grifoni, A., Tarke, A., Chang, J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.05.022 · Cited by 593 · see citing works

Innate immune mechanisms of mRNA vaccines

Verbeke, R., Hogan, M. J., Loré, K., & Pardi, N. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.014 · Cited by 518 · see citing works

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

Carreño, J. M., Alshammary, H., Tcheou, J., Singh, G., Raskin, A. J., Kawabata, H., Sominsky, L. A., Clark, J. J., Adelsberg, D. C., Bielak, D. A., et al. (2021) · Nature · doi:10.1038/s41586-022-04399-5 · Cited by 456 · see citing works

Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination

Röltgen, K., Nielsen, S. C. A., Silva, O., Younes, S. F., Zaslavsky, M., Costales, C., Yang, F., Wirz, O. F., Solis, D., Hoh, R. A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.018 · Cited by 459 · see citing works

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

Pajon, R., Doria-Rose, N. A., Shen, X., Schmidt, S. D., O’Dell, S., McDanal, C., Feng, W., Tong, J., Eaton, A., Maglinao, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119912 · Cited by 467 · see citing works

Covid-19 Vaccines — Immunity, Variants, Boosters

Barouch, D. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2206573 · Cited by 350 · see citing works

Divergent SARS-CoV-2 Omicron–reactive T and B cell responses in COVID-19 vaccine recipients

GeurtsvanKessel, C. H., Geers, D., Schmitz, K. S., Mykytyn, A. Z., Lamers, M. M., Bogers, S., Scherbeijn, S. M. J., Gommers, L., Sablerolles, R. S. G., Nieuwkoop, N. N., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo2202 · Cited by 401 · see citing works

Population Immunity and Covid-19 Severity with Omicron Variant in South Africa

Madhi, S. A., Kwatra, G., Myers, J. E., Jassat, W., Dhar, N., Mukendi, C. K., Nana, A. J., Blumberg, L., Welch, R., Ngorima-Mabhena, N., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2119658 · Cited by 404 · see citing works

Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)

Miller, J. M., Binnicker, M. J., Campbell, S. M., Carroll, K. C., Chapin, K. C., Gonzalez, M. D., Harrington, A., Jerris, R. C., Kehl, S. C., Leal, S. M., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae104 · Cited by 419 · see citing works

Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells

(2021) · doi:10.1126/science.abj9853 · Cited by 327 · see citing works

SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact

Lipsitch, M., Krammer, F., Regev‐Yochay, G., Lustig, Y., & Balicer, R. D. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00662-4 · Cited by 340 · see citing works

Correlates of protection against SARS‐CoV‐2 infection and COVID‐19 disease

Goldblatt, D., Alter, G., Crotty, S., & Plotkin, S. A. (2022) · Immunological Reviews · doi:10.1111/imr.13091 · Cited by 300 · see citing works

Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost

Muecksch, F., Wang, Z., Cho, A., Gaebler, C., Ben Tanfous, T., DaSilva, J., Bednarski, E., Ramos, V., Zong, S., Johnson, B., et al. (2022) · Nature · doi:10.1038/s41586-022-04778-y · Cited by 297 · see citing works

A lab-on-a-chip for the concurrent electrochemical detection of SARS-CoV-2 RNA and anti-SARS-CoV-2 antibodies in saliva and plasma

Najjar, D., Rainbow, J., Sanjay, S. T., Jolly, P., de Puig, H., Yafia, M., Durr, N., Sallum, H. M., Alter, G., Li, J. Z., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00919-w · Cited by 292 · see citing works

Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models

Cohen, A. A., van Doremalen, N., Greaney, A. J., Andersen, H., Sharma, A., Starr, T. N., Keeffe, J. R., Fan, C., Schulz, J. E., Gnanapragasam, P. N. P., et al. (2022) · Science · doi:10.1126/science.abq0839 · Cited by 259 · see citing works

mRNA Vaccines in the COVID-19 Pandemic and Beyond

Hogan, M. J., & Pardi, N. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042420-112725 · Cited by 252 · see citing works

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines

Wei, J., Pouwels, K. B., Stoesser, N. E., Matthews, P. C., Diamond, I. D., Studley, R., Rourke, E. D., Cook, D., Bell, J. I., Newton, J. N., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01721-6 · Cited by 236 · see citing works

Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors

Shroff, R. T., Chalasani, P., Wei, R., Pennington, D., Quirk, G., Schoenle, M. V., Peyton, K. L., Uhrlaub, J. L., Ripperger, T. J., Jergović, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01542-z · Cited by 233 · see citing works

A Covid-19 Milestone Attained — A Correlate of Protection for Vaccines

Gilbert, P. B., Donis, R. O., Koup, R. A., Fong, Y., Plotkin, S. A., & Follmann, D. A. (2022) · New England Journal of Medicine · doi:10.1056/nejmp2211314 · Cited by 217 · see citing works

Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection

Israel, A., Shenhar, Y., Green, I., Merzon, E., Golan‐Cohen, A., Schäffer, A. A., Ruppin, E., Vinker, S., & Magen, E. (2021) · Vaccines · doi:10.3390/vaccines10010064 · Cited by 218 · see citing works

Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection

Zhang, A., Stacey, H. D., D’Agostino, M. R., Tugg, Y., Marzok, A., & Miller, M. S. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00813-1 · Cited by 212 · see citing works

COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection

Chi, W.-Y., Li, Y.-D., Huang, H., Chan, T. E. H., Chow, S.-Y., Su, J.-H., Ferrall, L., Hung, C., & Wu, T. ‐. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00853-8 · Cited by 216 · see citing works

Structural Diversity of the SARS-CoV-2 Omicron Spike

Gobeil, S., Henderson, R. C., Stalls, V., Janowska, K., Huang, X., May, A. J., Speakman, M., Beaudoin, E. L., Manne, K., Li, D., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.03.028 · Cited by 198 · see citing works

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

Fendler, A., de Vries, E. G. E., GeurtsvanKessel, C. H., Haanen, J. B. A. G., Wormann, B. J., Turajlic, S., & von Lilienfeld‐Toal, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00610-8 · Cited by 205 · see citing works

Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes

Quandt, J., Muik, A., Salisch, N. C., Lui, B. G., Lutz, S., Krüger, K., Wallisch, A.-K., Adams‐Quack, P., Bacher, M., Finlayson, A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abq2427 · Cited by 191 · see citing works

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron

Gagné, M., Moliva, J. I., Foulds, K. E., Andrew, S. F., Flynn, B. J., Werner, A. P., Wagner, D. A., Teng, I., Lin, B. C., Moore, C. A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.038 · Cited by 206 · see citing works

COVID-19 vaccination: The road ahead

Altmann, D. M., & Boyton, R. J. (2022) · Science · doi:10.1126/science.abn1755 · Cited by 195 · see citing works

Imprinted SARS-CoV-2-Specific Memory Lymphocytes Define Hybrid Immunity

Rodda, L. B., Morawski, P. A., Pruner, K. B., Fahning, M. L., Howard, C. A., Franko, N., Logue, J. K., Eggenberger, J., Stokes, C., Golez, I., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.018 · Cited by 191 · see citing works

A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike

Dadonaite, B., Crawford, K. H. D., Radford, C. E., Farrell, A. G., Yu, T. C., Hannon, W. W., Zhou, P.-P., Andrabi, R., Burton, D. R., Liu, L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.02.001 · Cited by 182 · see citing works

The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant

Sanders, J., Bemelman, F. J., Messchendorp, A. L., Baan, C. C., van Baarle, D., van Binnendijk, R. S., Diavatopoulos, D. A., Frölke, S. C., Geers, D., GeurtsvanKessel, C. H., et al. (2021) · Transplantation · doi:10.1097/tp.0000000000003983 · Cited by 182 · see citing works

T Cell Responses to SARS-CoV-2

Sette, A., Sidney, J., & Crotty, S. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-061120 · Cited by 181 · see citing works

The Evolution and Biology of SARS-CoV-2 VariantsPreprint

Telenti, A., Hodcroft, E. B., & Robertson, D. L. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041390 · Cited by 182 · see citing works

Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events

Ng, S. C., Peng, Y., Zhang, L., Mok, C. K. P., Zhao, S., Li, A., Ching, J. Y. L., Liu, Y., Yan, S., Chan, D. L. S., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-326563 · Cited by 177 · see citing works

Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age

Creech, C. B., Anderson, E. J., Berthaud, V., Yildirim, I. B., Atz, A. M., Baez, I. M., Finkelstein, D., Pickrell, P., Kirstein, J., Yut, C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203315 · Cited by 174 · see citing works

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

Lyke, K. E., Atmar, R. L., Islas, C. D., Posavad, C. M., Szydlo, D., Paul Chourdhury, R., Deming, M. E., Eaton, A., Jackson, L. A., Branche, A. R., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100679 · Cited by 153 · see citing works

Towards a population-based threshold of protection for COVID-19 vaccines

Goldblatt, D., Fiore-Gartland, A. J., Johnson, M., Hunt, A., Bengt, C., Zavadska, D., Snipe, H. D., Brown, J., Workman, L., Zar, H. J., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.12.006 · Cited by 165 · see citing works

Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines

Bowen, J. E., Addetia, A., Dang, H. V., Stewart, C., Brown, J. T., Sharkey, W. K., Sprouse, K. R., Walls, A. C., Mazzitelli, I. G., Logue, J. K., et al. (2022) · Science · doi:10.1126/science.abq0203 · Cited by 158 · see citing works

Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants

Servellita, V., Syed, A. M., Morris, M. K., Brazer, N., Saldhi, P., Garcia-Knight, M., Sreekumar, B. K. N., Khalid, M. M., Ciling, A., Chen, P., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.019 · Cited by 155 · see citing works

Shedding of infectious SARS-CoV-2 despite vaccination

Riemersma, K. K., Haddock, L. A., Wilson, N. A., Minor, N. R., Eickhoff, J. C., Grogan, B., Kita-Yarbro, A., Halfmann, P., Segaloff, H. E., Kocharian, A., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010876 · Cited by 161 · see citing works

Antiviral neutralizing antibodies: from in vitro to in vivo activity

Burton, D. R. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00858-w · Cited by 152 · see citing works

Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection

Khoury, D. S., Schlub, T. E., Cromer, D., Steain, M. C., Fong, Y., Gilbert, P. B., Subbarao, K., Triccas, J. A., Kent, S. J., & Davenport, M. P. (2023) · Emerging infectious diseases · doi:10.3201/eid2902.221422 · Cited by 148 · see citing works

Characterization of nanoparticles-based vaccines for COVID-19

Guerrini, G., Magrì, D., Gioria, S., Medaglini, D., & Calzolai, L. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01129-w · Cited by 153 · see citing works

Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease

Zhou, P.-P., Song, G., Liu, H., Yuan, M., He, W., Beutler, N., Zhu, X., Tse, L. V., Martinez, D. R., Schäfer, A., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.02.005 · Cited by 151 · see citing works

mRNA vaccine in cancer therapy: Current advance and future outlook

Li, Y., Wang, M., Peng, X., Yang, Y., Chen, Q., Liu, J., She, Q., Tan, J., Lou, C., Liao, Z., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1384 · Cited by 152 · see citing works

Antibody-mediated neutralization of SARS-CoV-2

Gruell, H., Vanshylla, K., Weber, T., Barnes, C. O., Kreer, C., & Klein, F. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.005 · Cited by 145 · see citing works

Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies

Tada, T., Zhou, H., Dcosta, B. M., Samanovic, M. I., Chivukula, V., Herati, R. S., Hubbard, S. R., Mulligan, M. J., & Landau, N. R. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103944 · Cited by 132 · see citing works

Characterization of the significant decline in humoral immune response six months post‐SARS‐CoV‐2 mRNA vaccination: A systematic review

Notarte, K. I., Guerrero‐Arguero, I., Velasco, J. V., Ver, A. T., de Oliveira, M. H. S., Catahay, J. A., Khan, M. S. R., Pastrana, A. M., Juszczyk, G., Torrelles, J. B., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27688 · Cited by 143 · see citing works

Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?

Kent, S. J., Khoury, D. S., Reynaldi, A., Juno, J. A., Wheatley, A. K., Stadler, E., John Wherry, E., Triccas, J., Sasson, S. C., Cromer, D., et al. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00716-1 · Cited by 139 · see citing works

Scientific rationale for developing potent RBD-based vaccines targeting COVID-19

Kleanthous, H., Silverman, J., Makar, K., Yoon, I., Jackson, N. A. C., & Vaughn, D. (2021) · npj Vaccines · doi:10.1038/s41541-021-00393-6 · Cited by 137 · see citing works

Neutralising antibodies predict protection from severe COVID-19

Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Sasson, S. C., Kent, S. J., Khoury, D. S., & Davenport, M. P. (2022) · doi:10.1101/2022.06.09.22275942 · Cited by 139 · see citing works

Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial

Follmann, D. A., Janes, H., Buhule, O. D., Zhou, H., Girard, B., Marks, K., Kotloff, K. L., Desjardins, M., Corey, L., Neuzil, K. M., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m22-1300 · Cited by 126 · see citing works

Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines

Lee, J., Woodruff, M. C., Kim, E. H., & Nam, J. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00999-x · Cited by 137 · see citing works

SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients

Ruether, D. F., Schaub, G., Duengelhoef, P. M., Haag, F., Brehm, T. T., Fathi, A., Wehmeyer, M. H., Jahnke-Triankowski, J., Mayer, L., Hoffmann, A., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.09.003 · Cited by 133 · see citing works

CD8 T cells contribute to vaccine protection against SARS-CoV-2 in macaques

Liu, J., Yu, J., McMahan, K., Jacob-Dolan, C., He, X., Giffin, V., Wu, C., Sciacca, M., Powers, O., Nampanya, F., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abq7647 · Cited by 132 · see citing works

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

Barnes, E. J., Goodyear, C. S., Willicombe, M. K., Gaskell, C., Siebert, S., de Silva, T. I., Murray, S. M., Rea, D. W., Snowden, J. A., Carroll, M. W., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02414-4 · Cited by 132 · see citing works

Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial

Chalkias, S., Eder, F. S., Essink, B. J., Khetan, S. K., Nestorova, B., Feng, J., Chen, X., Chang, Y., Zhou, H., Montefiori, D. C., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02031-7 · Cited by 130 · see citing works

Count on us: T cells in SARS-CoV-2 infection and vaccination

Kedzierska, K., & Thomas, P. G. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100562 · Cited by 124 · see citing works

Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition

Gilbert, P. B., Huang, Y., deCamp, A. C., Karuna, S., Zhang, Y., Magaret, C. A., Giorgi, E. E., Korber, B., Edlefsen, P. T., Rossenkhan, R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01953-6 · Cited by 122 · see citing works

Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study

Adams, K., Rhoads, J. P., Surie, D., Gaglani, M., Ginde, A. A., McNeal, T., Talbot, H. K., Casey, J. D., Zepeski, A., Shapiro, N. I., et al. (2022) · BMJ · doi:10.1136/bmj-2022-072065 · Cited by 115 · see citing works

Predicting the efficacy of variant-modified COVID-19 vaccine boosters

Khoury, D. S., Docken, S. S., Subbarao, K., Kent, S. J., Davenport, M. P., & Cromer, D. (2023) · Nature Medicine · doi:10.1038/s41591-023-02228-4 · Cited by 102 · see citing works

Immune Memory Response After a Booster Injection of mRNA-1273 for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

Chu, L., Montefiori, D., Huang, W., Nestorova, B., Chang, Y., Carfi, A., Edwards, D. K., Oestreicher, J., Legault, H., Girard, B., et al. (2021) · doi:10.1101/2021.09.29.21264089 · Cited by 105 · see citing works

Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

Fong, Y., Huang, Y., Benkeser, D. C., Carpp, L. N., Áñez, G., Woo, W., McGarry, A., Dunkle, L. M., Cho, I., Houchens, C. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35768-3 · Cited by 100 · see citing works

Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses

Tauzin, A., Gong, S. Y., Beaudoin-Bussières, G., Vézina, D., Gasser, R., Nault, L., Marchitto, L., Benlarbi, M., Chatterjee, D., Nayrac, M., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.12.004 · Cited by 103 · see citing works

Accelerated waning of the humoral response to COVID-19 vaccines in obesity

van der Klaauw, A. A., Horner, E. C., Pereyra-Gerber, P., Agrawal, U., Foster, W. S., Spencer, S., Vergese, B., Smith, M., Henning, E., Ramsay, I. D., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02343-2 · Cited by 102 · see citing works

Cryo-EM structures of SARS-CoV-2 Omicron BA.2 spike

Stalls, V., Lindenberger, J. J., Gobeil, S., Henderson, R. C., Parks, R., Barr, M., Deyton, M., Martin, M., Janowska, K., Huang, X., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111009 · Cited by 101 · see citing works

Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose

Lustig, Y., Gonen, T., Meltzer, L., Gilboa, M., Indenbaum, V., Cohen, C., Amit, S., Jaber, H., Doolman, R., Asraf, K., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01212-3 · Cited by 94 · see citing works

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

Carreño, J. M., Alshammary, H., Tcheou, J., Singh, G., Raskin, A. J., Kawabata, H., Sominsky, L. A., Clark, J., Adelsberg, D. C., Bielak, D. A., et al. (2021) · Nature · doi:10.1038/d41586-021-03846-z · Cited by 112 · see citing works

Differential neutralizing antibody responses elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in Chile

(2022) · doi:10.1038/s41564-022-01092-1 · Cited by 98 · see citing works

Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review

Pooley, N., Karim, S. S. A., Combadière, B., Ooi, E. E., Harris, R. C., Guerche‐Séblain, C. E., Kisomi, M., & Shaikh, N. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00753-2 · Cited by 93 · see citing works

Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies

Greenberger, L. M., Saltzman, L. A., Senefeld, J. W., Johnson, P. W., DeGennaro, L. J., & NICHOLS, G. L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.001 · Cited by 94 · see citing works

Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies

Chung, Y.-S., Lam, C.-Y., Tan, P.-H., Tsang, H. F., & Wong, S. C. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158155 · Cited by 100 · see citing works

ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines

Hoffmann, M. A. G., Yang, Z., Huey‐Tubman, K. E., Cohen, A. A., Gnanapragasam, P. N. P., Nakatomi, L. M., Storm, K. N., Moon, W. J., Lin, P. J. C., West, A. P., et al. (2023) · Cell · doi:10.1016/j.cell.2023.04.024 · Cited by 94 · see citing works

Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review

Perry, J. A., Osman, S., Wright, J., Richard‐Greenblatt, M., Buchan, S. A., Sadarangani, M., & Bolotin, S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266852 · Cited by 87 · see citing works

B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity

Lapuente, D., Winkler, T., & Tenbusch, M. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01095-w · Cited by 91 · see citing works

Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial

Fong, Y., McDermott, A. B., Benkeser, D. C., Roels, S., Stieh, D. J., Vandebosch, A., Gars, M. L., Roey, G. A. V., Houchens, C. R., Martins, K. A. O., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01262-1 · Cited by 91 · see citing works

Aging, inflammaging and immunosenescence as risk factors of severe COVID-19

Tizazu, A. M., Mengist, H. M., & Demeke, G. (2022) · Immunity & Ageing · doi:10.1186/s12979-022-00309-5 · Cited by 91 · see citing works

Recent updates on correlates of vaccine-induced protection

Plotkin, S. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1081107 · Cited by 89 · see citing works

Infectious Diseases Society of America Guidelines on the Diagnosis of Coronavirus Disease 2019: Serologic Testing

Hayden, M. K., Mikati, I. K. E., Hanson, K. E., Englund, J. A., Humphries, R. M., Lee, F., Loeb, M. B., Morgan, D. J., Patel, R., Ta’ani, O. A., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae121 · Cited by 89 · see citing works

A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability

Voigt, E. A., Gerhardt, A., Hanson, D., Jennewein, M. F., Battisti, P., Reed, S., Singh, J., Mohamath, R., Bakken, J., Beaver, S., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00549-y · Cited by 89 · see citing works

Vaccine protection against the SARS-CoV-2 Omicron variant in macaques

Chandrashekar, A., Yu, J.-Y., McMahan, K., Jacob-Dolan, C., Liu, J.-Y., He, X., Hope, D. L., Anioke, T., Barrett, J., Chung, B., et al. (2022) · bioRxiv · doi:10.1016/j.cell.2022.03.024 · Cited by 83 · see citing works

SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort

Aldridge, R. W., Yavlinsky, A., Nguyen, V. G., Eyre, M. T., Shrotri, M., Navaratnam, A. M. D., Beale, S., Braithwaite, I., Byrne, T., Kovar, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32265-5 · Cited by 83 · see citing works

Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial

Abhishek, A., Boyton, R. J., Peckham, N., McKnight, Á., Coates, L. C., Bluett, J., Barber, V. S., Cureton, L., Francis, A., Appelbe, D. E., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00186-2 · Cited by 83 · see citing works

Impact of aging on immunity in the context of COVID-19, HIV, and tuberculosis

Grifoni, A., Alonzi, T., Alter, G., Noonan, D. M., LANDAY, A. L., Albini, A., & Goletti, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1146704 · Cited by 87 · see citing works

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources

Sullivan, D. J., Franchini, M., Joyner, M. J., Casadevall, A., & Focosi, D. (2022) · Nature Communications · doi:10.1038/s41467-022-33864-y · Cited by 91 · see citing works

Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study

Barin, B., Kasap, U., Selçuk, F., Volkan, E., & Uluçkan, Ö. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00305-0 · Cited by 79 · see citing works

Design and lyophilization of lipid nanoparticles for mRNA vaccine and its robust immune response in mice and nonhuman primates

Suzuki, Y., Miyazaki, T., Muto, H., Kubara, K., Mukai, Y., Watari, R., Sato, S., Kondo, K., Tsukumo, S., Yasutomo, K., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.09.017 · Cited by 81 · see citing works

Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants

Miyamoto, S., Arashiro, T., Adachi, Y., Moriyama, S., Kinoshita, H., Kanno, T., Saito, S., Katano, H., Iida, S., Ainai, A., et al. (2022) · Med · doi:10.1016/j.medj.2022.02.006 · Cited by 68 · see citing works

Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia

Dashdorj, N., Wirz, O. F., Röltgen, K., Haraguchi, E., Buzzanco, A. S., Sibai, M., Wang, H., Miller, J. A., Solis, D., Sahoo, M. K., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.11.004 · Cited by 76 · see citing works

Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation

Huang, Y., Borisov, O., Kee, J. J., Carpp, L. N., Wrin, T., Cai, S., Sarzotti‐Kelsoe, M., McDanal, C. B., Eaton, A., Pajón, R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-03154-6 · Cited by 72 · see citing works

SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines

Bowen, J. E., Park, Y., Stewart, C., Brown, J. T., Sharkey, W. K., Walls, A. C., Joshi, A., Sprouse, K. R., McCallum, M., Tortorici, M. A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.adf1421 · Cited by 81 · see citing works

Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study

Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Coyle, P., Tang, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., Al-Kanaani, Z., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00287-7 · Cited by 76 · see citing works

The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future

Antinori, A., & Bausch-Jurken, M. T. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad181 · Cited by 76 · see citing works

Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections

Stærke, N. B., Reekie, J., Nielsen, H., Benfield, T., Wiese, L., Knudsen, L. S., Iversen, M. B., Iversen, K. K., Fogh, K., Bodilsen, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32254-8 · Cited by 73 · see citing works

Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial

Benkeser, D. C., Montefiori, D. C., McDermott, A. B., Fong, Y., Janes, H., Deng, W., Zhou, H., Houchens, C. R., Martins, K. A. O., Jayashankar, L., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.ade9078 · Cited by 43 · see citing works

Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

Fong, Y., Huang, Y., Benkeser, D. C., Carpp, L. N., Áñez, G., Woo, W., McGarry, A., Dunkle, L. M., Cho, I., Houchens, C. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35768-3 · Cited by 100 · see citing works

Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial

Huang, Y., Hejazi, N. S., Blette, B. S., Carpp, L. N., Benkeser, D. C., Montefiori, D. C., McDermott, A. B., Fong, Y., Janes, H., Deng, W., et al. (2023) · Viruses · doi:10.3390/v15102029 · Cited by 15 · see citing works

Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE TrialPreprint

Sahly, H. M. E., Baden, L. R., Essink, B. J., Montefiori, D. C., McDermont, A., Rupp, R. E., Lewis, M., Swaminathan, S., Griffin, C., Fragoso, V. G., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3988003 · Cited by 2 · see citing works

Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine

Ma, C., Feng, J., Wahid, R., Chalkias, S., Edwards, D., Girard, B., Das, R., Zhou, H., & Zheng, L. (2026) · Figshare · doi:10.6084/m9.figshare.32531162